857728--3/3/2006--I_FLOW_CORP_/DE/

related topics
{stock, price, share}
{regulation, government, change}
{customer, product, revenue}
{regulation, change, law}
{operation, international, foreign}
{condition, economic, financial}
{property, intellectual, protect}
{tax, income, asset}
{cost, regulation, environmental}
{control, financial, internal}
{acquisition, growth, future}
{provision, law, control}
{product, market, service}
{competitive, industry, competition}
Our customers frequently receive reimbursement from private insurers and governmental agencies. Any change in the overall reimbursement system may adversely impact our business. Changes in reimbursement rates may adversely impact InfuSystem s revenues. Changes in reimbursement rates may adversely impact the revenue that we earn from our developing billing strategy for ON-Q. Our products are highly regulated by a number of governmental agencies. Any changes to the existing rules and regulations of these agencies may adversely impact our ability to manufacture and market our products. Our compliance with laws frequently involves our subjective judgment. If we are wrong in any of our interpretations of the laws, we could be subjected to substantial penalties for noncompliance. We may need to raise additional capital in the future to fund our operations. We may be unable to raise funds when needed or on acceptable terms. Our intangible assets are subject to potential impairment charges that could adversely affect our results of operations. Our industry is intensely competitive and changes rapidly. If we are unable to maintain a technological lead over our competitors, our business operations will suffer. We rely on independent suppliers for parts and materials necessary to assemble our products. Any delay or disruption in the supply of parts may prevent us from manufacturing our products and negatively impact our operations. Our success in the Oncology Infusion Services market is impacted by the availability of the chemotherapy drugs that are used in our infusion pump systems. We manufacture the majority of our products in Mexico. Any difficulties or disruptions in the operation of our plant may adversely impact our operations. If one of our products proves to be defective or is misused by a health care practitioner or patient, we may be subject to claims of liability that could adversely affect our financial condition and the results of our operations. We are dependent on our proprietary technology and the patents, copyrights, and trademarks that protect our products. If competitors are able to independently develop products of equivalent or superior capabilities, the results of our operations could be adversely impacted. A significant portion of our sales is to customers in foreign countries. We may lose revenues, market share, and profits due to exchange rate fluctuations and other factors related to our foreign business. We currently rely on two distributors for a significant percentage of our sales. If our relationship with these distributors were to deteriorate, our sales may materially decline. The preparation of our financial statements in accordance with accounting principles generally accepted in the United States requires us to make estimates, judgments, and assumptions that may ultimately prove to be incorrect. Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and our stock price. RISK FACTORS RELATED SPECIFICALLY TO OUR COMMON STOCK The average trading volume for our common stock is relatively low when compared to most larger companies. As a result, there may be less liquidity and more volatility associated with our common stock, even if our business is doing well. Future sales of our common stock by existing stockholders could negatively affect the market price of our stock and make it more difficult for us to sell stock in the future. Anti-takeover devices may prevent a sale, or changes in the management, of I-Flow. We do not pay dividends and this may negatively affect the price of our stock. In the future, our common stock may be removed from listing on the Nasdaq quotation system and may not qualify for listing on any stock exchange, in which case it may be difficult to find a market in our stock.

Full 10-K form ▸

related documents
857728--3/17/2008--I_FLOW_CORP_/DE/
857728--3/30/2007--I_FLOW_CORP_/DE/
1013556--4/17/2007--COMMODORE_APPLIED_TECHNOLOGIES_INC
822418--3/5/2009--BIO_IMAGING_TECHNOLOGIES_INC
777491--2/27/2006--CH2M_HILL_COMPANIES_LTD
2186--3/14/2006--RELM_WIRELESS_CORP
822418--3/29/2007--BIO_IMAGING_TECHNOLOGIES_INC
1109153--3/31/2009--BIOPACK_ENVIRONMENTAL_SOLUTIONS_INC.
1109153--3/31/2010--BIOPACK_ENVIRONMENTAL_SOLUTIONS_INC.
822418--3/5/2008--BIO_IMAGING_TECHNOLOGIES_INC
96057--10/4/2006--SYS
2186--3/7/2007--RELM_WIRELESS_CORP
2186--3/5/2008--RELM_WIRELESS_CORP
737561--4/8/2010--UCI_MEDICAL_AFFILIATES_INC
851520--2/24/2010--EXPONENT_INC
1035092--3/16/2007--SHORE_BANCSHARES_INC
75439--3/31/2009--CytoCore_Inc
1126983--10/13/2006--NEW_MEDIUM_ENTERPRISES_INC
857728--3/10/2009--I_FLOW_CORP_/DE/
924383--1/8/2007--AMERICAN_TECHNOLOGY_CORP_/DE/
826253--6/15/2009--AURA_SYSTEMS_INC
1103345--3/15/2010--BEACON_POWER_CORP
1089473--3/16/2006--VENTIV_HEALTH_INC
1047919--3/11/2009--AMBIENT_CORP_/NY
1089473--2/28/2007--INVENTIV_HEALTH_INC
1011733--4/15/2009--TRIMOL_GROUP_INC
352998--3/31/2009--IGI_INC
769592--6/29/2007--MOBILEPRO_CORP
1079028--11/26/2008--VARIAN_INC
737561--2/2/2010--UCI_MEDICAL_AFFILIATES_INC